7-methyl-6-phenyl-pteridine-2,4-diamine | 1029-87-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 蝶啶及其衍生物
• 英文名称: 7-methyl-6-phenyl-pteridine-2,4-diamine
• 英文别名: 7-methyl-6-phenyl-pteridine-2,4-diyldiamine；7-Methyl-6-phenyl-pteridin-2,4-diyldiamin；2,4-diamino-6-phenyl-7-methylpteridine；2,4-Diamino-7-methyl-6-phenyl-pteridin；7-Methyl-6-phenylpteridine-2,4-diamine
• CAS: 1029-87-4
• 化学式: C₁₃H₁₂N₆
• 分子量: 252.278
• InChiKey: TXMJBZJNWIOSBI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  104
• 氢给体数：
  2
• 氢受体数：
  6

安全信息

• 海关编码：
  2933990090

反应信息

• 作为产物：
  描述：

  5-亚硝基-2,4,6-三氨基嘧啶 、 苯基丙酮 在 盐酸 、 溶剂黄146 作用下， 生成 7-methyl-6-phenyl-pteridine-2,4-diamine
  参考文献：
  名称：

  Method of preparing pyrimidopyrazines

  摘要：

  公开号：

  US02581889A1

文献信息

• Immunosuppressive effects of pteridine derivatives
  申请人：——

  公开号：US20040077859A1

  公开（公告）日：2004-04-22

  This invention relates to a group of trisubstituted and tetrasubstituted pteridine derivatives, their pharmaceutically acceptable salts, N-oxides, solvates, dihydro- and tetrahydroderivatives and enantiomers, possessing unexpectedly desirable pharmaceutical properties, in particular which are highly active immunosuppressive agents, and as such are useful in the treatment in transplant rejection and/or in the treatment of certain inflammatory diseases. These compounds are also useful in preventing or treating cardiovascular disorders, allergic conditions, disorders of the central nervous system and cell proliferative disorders.

  这项发明涉及一组三取代和四取代的嘌呤衍生物，它们的药用盐、N-氧化物、溶剂化物、二氢和四氢衍生物及对映异构体，具有意想不到的、令人满意的药理性质，尤其是作为高度活性的免疫抑制剂，因此可用于治疗移植排斥反应和/或治疗某些炎症性疾病。这些化合物还用于预防或治疗心血管疾病、过敏性疾病、中枢神经系统疾病和细胞增殖紊乱。
• Inhibition of Neuronal Nitric Oxide Synthase by 4-Amino Pteridine Derivatives:  Structure−Activity Relationship of Antagonists of (6<i>R</i>)-5,6,7,8-Tetrahydrobiopterin Cofactor
  作者：Lothar G. Fröhlich、Peter Kotsonis、Hermann Traub、Shahriyar Taghavi-Moghadam、Najim Al-Masoudi、Heinrich Hofmann、Hartmut Strobel、Hans Matter、Wolfgang Pfleiderer、Harald H. H. W. Schmidt

  DOI：10.1021/jm981129a

  日期：1999.10.1

  The family of nitric oxide synthases (NOS) catalyzes the conversion of L-arginine to L-citrulline and nitric oxide (NO), an important cellular messenger molecule which has been implicated in the pathophysiology of septic shock and inflammatory and neurodegenerative disease states. NOS can be maximally activated by the ubiquitous cofactor, (6R)-5,6,7,8-tetrahydrobiopterin (H(4)Bip), and antagonists of H(4)Bip may be of therapeutic importance to inhibit pathologically high NO formation. The 4-amino substituted analogue of H(4)Bip was reported to be a potent NOS inhibit-or. Therefore, we developed a series of novel 4-amino pteridine derivatives, antipterins, to pharmacologically target the neuronal isoform of nitric oxide synthase (NOS-I). To functionally characterize the pterin/anti-pterin interaction and establish a structure-activity relationship (SAR), we systematically altered the substituents in the 2-, 4-, 5-, 6-, and 7-position of the pteridine nucleus. Varying the substitution pattern in the 2-, 5-, and 7-position resulted in no significant inhibitory effect on enzyme activity. In contrast, bulky substituents in the B-position, such as phenyl, markedly increased the inhibitory potency of the reduced 4-amino-5,6,7,8-tetrahydropteridines, possibly as a consequence of hydrophobic interactions within NOS-I. However, this was not the case for the aromatic 4-amino pteridines. Interestingly, chemical modification of the 4-amino substituent by dialkyl/diaralkylation together with 6-arylation of the aromatic 2,4-diamino pteridine resulted in potent and efficacious inhibitors of NOS-I, suggesting possible hydrophilic and hydrophobic interactions within NOS-I. This SAR agrees with (a) the recently published crystal structure of the oxygenase domain of the inducible NOS isoform (NOS-II) and (b) the comparative molecular field analysis of selected NOS-I inhibitors, which resulted in a 3D-QSAR model of the pterin binding site interactions. Further optimization should be possible when the full length structure of NOS-I becomes available.
• IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES
  申请人：4 AZA Bioscience nv

  公开号：EP1658081A2

  公开（公告）日：2006-05-24
• PTERIDINE DERIVATIVES FOR THE TREATMENT OF SEPTIC SHOCK AND TNF-ALPHA-RELATED DISEASES.
  申请人：4 AZA Bioscience nv

  公开号：EP1663244A2

  公开（公告）日：2006-06-07
• [EN] IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES<br/>[FR] EFFETS IMMUNOSUPPRESSIFS DE DERIVES DE PTERIDINE
  申请人：4 AZA BIOSCIENCE NV

  公开号：WO2005021003A2

  公开（公告）日：2005-03-10

  This invention relates to a group of trisubstituted and tetrasubstituted pteridine derivatives, their pharmaceutically acceptable salts, N-oxides, solvates, dihydro- and tetrahydro- derivatives and enantiomers, possessing unexpectedly desirable pharmaceutical properties, in particular which are highly active immunosuppressive agents, and as such are useful in the treatment in transplant rejection and/or in the treatment of certain inflammatory diseases. These compounds are also useful in preventing or treating cardiovascular disorders, allergic conditions, disorders of the central nervous system and cell proliferative disorders.